Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas and ... a nighttime-specific product that targets fat cells for extreme contouring action. During sleep ... fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... Nearly ... of serious diseases. Yet few people realize that a rich source of these cells ... young adults, and teeth that need to be pulled to make room for braces. ...
(Date:7/28/2015)... INCLINE VILLAGE, Nev. , July 28, 2015 /PRNewswire/ ... PDLI ) today announced that the Company will release ... ended June 30, 2015, on Wednesday, August 5, 2015, ... call and webcast that day at 4:30 p.m. Eastern ... relating to the call will be available via the ...
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Toothâ„¢ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... Inc., a,developer and manufacturer of specialized short-wavelength light ... that enables light sources to achieve extreme high ... The LDLS(TM) Laser-Driven,Light Source is embodied in the ... compact light products that can be used in ...
... Inc. (Nasdaq:,CEPH) announced today that the U.S. ... formulation patent for AMRIX(R) (Cyclobenzaprine,Hydrochloride Extended-Release Capsules). ... Inc., the developer of AMRIX, and expires ... an exclusive license from Eurand to,market AMRIX ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), a ... it is expanding its clinical pharmacology,capabilities in ... PAREXEL,is enhancing existing services in early phase ... combining traditional pharmacodynamic,methods with relevant biomarkers, which ...
Cached Biology Technology:Energetiq's Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet 2Cephalon Announces Issuance of Patent for AMRIX 2Cephalon Announces Issuance of Patent for AMRIX 3PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies 2PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies 3PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies 4
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... research at York has revealed so-called Jekyll and Hyde ... without using insecticides. Researchers at the University of ... bacteria that live in them and discovered an ... insects. In fact, many insects thrive on plant food ...
... poll to reflect the discovery reported internationally in November ... stem cells or their near equivalents. When asked about ... 10, or 63 percent, say that both embryonic and ... say this development means embryonic stem cell research is ...
... RFID FOR STOCK ... AND STORE FRONT SOLUTION, SAN JOSE, Calif., Dec. 18 ... provider announced today the launch of a new product tailor-made,for the ... purpose is to provide the retail industry a total solution for,efficient ...
Cached Biology News:Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows 2Titanium Group Announces Launch of New Identification Solution Targeting High Growth Retail Sector 2Titanium Group Announces Launch of New Identification Solution Targeting High Growth Retail Sector 3
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
Biology Products: